Maganin CAR-T don Ciwon Ciki

Claudin18.2 (CLDN18.2) wani sinadari ne mai hade da furotin wanda aka bayyana musamman a cikin epithelium na ciki kuma yana da yawan fitowa a saman ƙwayoyin cutar kansar ciki. CT041 (lambar ci gaba CG4006) samfurin CAR-T ne wanda ke nufin CLDN18.2. Bayanan Mataki na I sun nuna kyakkyawan aikin hana ƙari ga masu fama da cutar kansar ciki da aka riga aka yi musu magani, CLDN18.2 masu dauke da cutar kansar ciki.

Ana kuma ganin yawan HER2 a cikin wasu marasa lafiya da ke fama da ciwon daji na ciki. Magungunan CAR-T da aka yi niyya ga HER2 sun nuna yuwuwar hana ciwon daji a cikin binciken asibiti na farko da na farko. TAC01-HER2 na Triumvira Immunologics a halin yanzu yana cikin gwaje-gwajen asibiti na Mataki na II.

• Manufa Mai Musamman: Ta hanyar jagorantar ƙwayoyin CAR-T akan CLDN18.2 ko HER2, ana iya gano ƙwayoyin cutar kansar ciki daidai kuma a kawar da su, ta haka rage tasirin da ke tattare da ƙari.

• Cin Nasara Kan Juriyar Jiyya Mai Layi Da YawaA cikin gwaje-gwajen CT041, ƙungiyar ciwon daji ta ciki ta cimma ƙimar amsawa ta gaskiya (ORR) na 57.1%, ƙimar kula da cututtuka (DCR) na 75.0%, da kuma tsawon watanni 6 na rayuwa (OS) na 81.2% a cikin marasa lafiya waɗanda suka gaza a cikin layukan magani da yawa a baya.

• Amsoshi Masu Dorewa: Maganin CLDN18.2-CAR-T ya samar da tsawon watanni 6 na amsawa na 44.8%, wanda ke nuna yuwuwar samun fa'ida ta asibiti na dogon lokaci.

• Jiyya ta Musamman: Amfani da ƙwayoyin T na majiyyaci yana rage haɗarin ƙin yarda da shi kuma yana ƙara aminci da inganci.

• Tarin Kwayoyin T na Jini na Gefe
  Ana ware ƙwayoyin T daga jinin majiyyaci ta hanyar leukapheresis.

• Injiniyan Halitta
  A cikin dakin gwaje-gwajen da ya dace da GMP, ana canza ƙwayoyin T don bayyana CAR da ke nufin CLDN18.2 ko HER2, sannan a faɗaɗa ex vivo.

• Yanayin Lymphodepleting
  Ana amfani da tsarin shirya cyclophosphamide da fludarabine don rage ƙwayoyin lymphocytes na ciki da kuma ƙirƙirar wuri mai kyau don faɗaɗa ƙwayoyin CAR-T.

• Jiko na CAR-T Cell
  Ana mayar da ƙwayoyin CAR-T da aka ƙera cikin majiyyaci ta hanyar jijiya.

• Kulawa da Gudanarwa
  Bayan an yi amfani da maganin, ana sa ido sosai kan marasa lafiya game da cutar sakin cytokine (CRS) da kuma gubar jijiyoyi, tare da yin amfani da hanyoyin da suka dace idan ya cancanta.

• Binciken Wucin Gadi na Mataki na I na CT041 (CLDN18.2-CAR-T)
  Daga cikin marasa lafiya 37 da aka yi wa magani kafin a fara yi musu magani, ƙungiyar ciwon daji ta ciki ta sami ORR 57.1%, DCR 75.0%; 94.6% sun sami CRS na aji 1-2 kawai, ba tare da CRS na aji 3 ko sama da haka ko guba ba; tsawon lokacin amsawar watanni 6 shine 44.8%.

• Sakamakon Ƙarshe na Mataki na I na Satri-cel (wanda kuma aka yi niyya ga CLDN18.2)
  A cikin marasa lafiya 98 da ke fama da cutar kansar ciki ta CLDN18.2 masu dauke da cutar, ORR ya kai kashi 38.8%, DCR 91.8%; matsakaicin rayuwa ba tare da ci gaba ba (mPFS) ya kai watanni 4.4 (95% CI 3.7–6.6), matsakaicin rayuwa gaba daya (mOS) ya kai watanni 8.8 (95% CI 7.1–10.2); 96.9% sun sami CRS na aji 1–2 kawai, ba tare da CRS na aji 3+ ko mace-mace masu alaƙa ba.

• Bayanan Asibiti na Farko na HER2-CAR-T
  Nazarin Mataki na farko a cikin ɗan adam ya nuna yanayin tsaro mai kyau; ana ci gaba da gwajin rajista na Mataki na II.

• Babban Dandalin Fasaha
  BIOOCUS tana gudanar da wani kamfanin kera maganin ƙwayoyin halitta na duniya na matakin GMP, wanda ke tabbatar da ingantaccen samar da ƙwayoyin CAR-T cikin inganci da daidaito.

• Ƙungiyar Ƙwararrun Ma'aikata Masu Nasara Daban-daban
  Ƙungiyarmu ta haɗa da ƙwararru a fannin rigakafi, ciwon daji, da kuma maganin ƙwayoyin halitta, waɗanda ke ba da cikakken kulawa ta musamman.

• Kwarewar Asibiti ta Duniya
  Mun yi wa marasa lafiya magani daga ko'ina cikin duniya, muna tattara bayanai masu yawa game da aminci da inganci.

• Cikakken Sabis na Ƙarshe-zuwa-Ƙarshe
  Tun daga tsarin tsara yarjejeniya da kuma daidaita jiyya a ƙasashen waje zuwa bin diddigin allurar bayan allurar, BIOOCUS yana ba da tallafi na dindindin.